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The M protein of Streptococcus equi subsp. equi known as
fibrinogen-binding protein (FgBP) is a cell wall-associated pro-
tein with antiphagocytic activity that binds IgG. Recombinant
versions of the seven equine IgG subclasses were used to inves-
tigate the subclass specificity of FgBP. FgBP bound predomi-
nantly to equine IgG4 and IgG7, with little or no binding to the
other subclasses. Competitive binding experiments revealed
that FgBP could inhibit the binding of staphylococcal protein A
and streptococcal protein G to both IgG4 and IgG7, implicating
the Fc interdomain region in binding to FgBP. To identify which
of the two IgG Fc domains contributed to the interaction with
FgBP, we tested two human IgG1/IgA1 domain swap mutants
and found that both domains are required for full binding, with
the CH3 domain playing a critical role. The binding site for
FgBPwas further localizedusing recombinant equine IgG7 anti-
bodies with single or double pointmutations to residues lying at
theCH2-CH3 interface.We found that interaction of FgBPwith
equine IgG4 and IgG7was able to disrupt C1q binding and anti-
body-mediated activation of the classical complement pathway,
demonstrating an effective means by which S. equi may evade
the immune response.Themodeof interactionof FgBPwith IgG
fits a common theme for bacterial Ig-binding proteins. Remark-
ably, for those interactions studied in detail, it emerges that all
the Ig-binding proteins target the CH2-CH3 domain interface,
regardless of specificity for IgG or IgA, streptococcal or staphy-
lococcal origin, or host species (equine or human).
Strangles is a highly contagious upper respiratory tract dis-
ease of the horse and is caused by Streptococcus equi subsp.
equi, a Lancefield group C streptococcus. The disease is char-
acterized by fever, mucopurulent nasal discharge, and the for-
mation of abscesses in lymph nodes of the head and neck. It is
one of the most frequently reported equine clinical problems
worldwide and is associated with serious economic cost,
because severe outbreaks may last for months or years (1–3). A
proportion of horses that recover from strangles become per-
sistent carriers of S. equi, capable of infecting naı¨ve horses and
continuing the spread of the disease (4). Complications can
occur in up to 20% of strangles cases and include formation of
abscesses in other body organs (“bastard strangles”) and pur-
pura hemorrhagica, an immune complex-mediated vasculitis
(3).
The S. equiMprotein, also known as fibrinogen-binding pro-
tein (FgBP),2 is a major cell wall-associated protein of S. equi
subsp. equi (5–7). It is 534 amino acids in length, contains two
blocks of degenerate repeated sequences, and, in commonwith
M-proteins of otherGram-positive streptococci, is predicted to
possess a non-helical N terminus and extensive regions of
-helical coiled-coil structure throughout the rest of the extra-
cellular portion of the protein (7, 8). FgBP plays a significant
role in the resistance of S. equi to phagocytosis and contributes
substantially to its virulence (9). TheN-terminal region of FgBP
is able to bind strongly to fibrinogen, and this appears to play an
important part in the antiphagocytic effect of the protein and
survival of S. equi in the host (6, 7, 10–12).
In addition to the binding of host fibrinogen, FgBP has been
demonstrated to bind to the Fc region of horse IgG, as well as
IgG from several other species (human, rabbit, and cat but not
mouse, rat, goat, sheep, cow, or chicken) (9). Hence FgBP rep-
resents another example of a bacterial Ig-binding protein. A
number of such proteins, produced by pathogenic staphylococ-
cal and streptococcal strains and including thewidely employed
staphylococcal protein A and streptococcal protein G, have
been described. The region of FgBP that binds to IgG Fc is
distinct from that responsible for fibrinogen binding and
involves the central part of the protein (8, 9). The development
of specific mucosal and systemic antibody responses is consid-
ered crucial for combating infection with S. equi and for pro-
tection from future disease (2). Significantly, a specific IgG
response has been shown to contribute to this protective
humoral immunity (13). The horse has seven IgG subclasses
(14, 15), and to date there is no information with regard to the
subclass specificity of FgBP and whether the interaction of
FgBP with IgG Fc contributes to subversion of the immune
response by S. equi. Here, we demonstrate that the binding of
FgBP to horse IgG is highly subclass specific and that the bind-
ing site for FgBP on horse IgG Fc is located in the interdomain* This work was supported by the Wellcome Trust (Grant 074863) and the
Privy Purse Charitable Trust. The costs of publication of this article were
defrayed in part by the payment of page charges. This article must there-
fore be hereby marked “advertisement” in accordance with 18 U.S.C. Sec-
tion 1734 solely to indicate this fact.
Author’s Choice—Final version full access.
1 To whom correspondence should be addressed: Tel.: 44-1382-660111 (ext.
33540); Fax: 44-1382-633952; E-mail: j.m.woof@dundee.ac.uk.
2 The abbreviations used are: FgBP, fibrinogen-binding protein; reqIgG,
recombinant equine IgG; reqIgA, recombinant equine IgA; PBS, phos-
phate-buffered saline; HRP, horseradish peroxidase; H-chain, heavy chain;
EAG,2-macroglobulin, albumin, and IgG-binding protein; ELISA, enzyme-
linked immunosorbent assay.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 25, pp. 17615–17623, June 20, 2008
Author’s Choice © 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
JUNE 20, 2008•VOLUME 283•NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 17615
 at UNIVERSITY O









region and overlaps with that of protein A andG. Furthermore,
binding of FgBP to horse IgG is able to disrupt antibody-medi-
ated complement activation suggesting another mechanism by
which FgBP can mediate resistance to phagocytosis and com-
promise the host immune response to S. equi subsp. equi.
EXPERIMENTAL PROCEDURES
Production of FgBPs—FgBP1, a recombinant form of FgBP
that lacks the wall/membrane anchor domain, was produced as
described previously (7). For generation of FgBPM, a recom-
binant form of FgBP that lacks the central domain between the
A and B repeats (amino acids 279–348) and does not bind to
equine IgG,3 FgBP gene sequences encoding amino acids
37–278 and 349–470 were amplified and juxtaposed in the
vector pQE30. Transformation of Escherichia coli XL-1Blue
with pQE30 and purification of the recombinant protein was
carried out as previously described (7, 11).
Analysis of the Interaction of FgBP with Recombinant Equine
Igs by ELISA—Interaction of FgBP1 with recombinant forms of
the seven equine IgG (reqIgG) subclasses, produced and puri-
fied as described previously (16), was analyzed by ELISA. FgBP1
(10 g/ml in carbonate buffer) was coated overnight at 4 °C
onto 96-well Maxisorp immunoplates (Nunc, Roskilde, Den-
mark). Control wells were coated with 10 g/ml FgBPM.
Plates were washed inMilli-Qwater and then blocked for 1 h at
room temperature with 5% nonfatmilk powder in PBS contain-
ing 0.5% Tween 20 (PBS-T). Plates were then incubated with
serial dilutions (0–20 g/ml in PBS-T) of one of the reqIgG
subclasses or recombinant equine monomeric equine IgA4
(eqIgA) for 1 h at room temperature. Binding of reqIgs to FgBP
was detected by incubation for 1 h at room temperature with
HRP-conjugated goat anti-mouse  light chain antibody (0.2
g/ml in PBS-T) (Bethyl Laboratories Inc., Montgomery, TX).
Goat IgG does not bind to FgBP (9) and so was suitable as the
detection reagent in these experiments. Plates were developed
as previously described (17). The pH dependence of the FgBP-
IgG interaction was analyzed using the same ELISA except that
reqIgGs (serial dilutions of 0–10 g/ml) were diluted in PBS-T
at either pH 5.5, pH 7.4, or pH 8.5, and FgBP1 and FgBPM
were used at 5 g/ml.
Biosensor Analysis of FgBP1 Binding to reqIgG—Biosensor
experiments were carried out using a BIAcore X instrument
(BIAcoreAB, Uppsala, Sweden). Recombinant FgBP1 (20M in
10 mM sodium acetate, pH 5.5) was immobilized on a CM5
biosensor chip (BIAcore) using themanufacturer’s instructions
for amine coupling chemistry. Recombinant FgBPMwas cou-
pled under the same conditions to the reference surface of the
chip. Recombinant eqIgGs were diluted in BIAcore HBS-EP
buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% sur-
factant P20) across a concentration range of 0–150 g/ml and
were independently injected over the chip (60 l and 30
l/min). After each injection the sensor chip was regenerated
with 20l of 10 mM glycine, pH 3, followed by a 10-l injection
of 10mMglycine, pH2, if required. Biosensor analysis of recom-
binant human IgG1 (18) binding to FgBP1 was also carried out
as described above. BIAevaluation 3.2 software was used for
data analysis.
Protein G and Protein A Competition ELISAs—Plates were
coated with 2.5 g/ml of either reqIgG4 or reqIgG7 and then
washed and blocked as described above. Plates were placed on
ice, and 100 l/well ice-cold HRP-conjugated protein G (0.25
g/ml in PBS-T) (Sigma), and serial dilutions of either FgBP1 or
FgBPM (both0–50g/ml inPBS-T)were added simultaneously
to each well. Plates were incubated for 2 h at room temperature
and then developed as described above. A similar ELISAwas used
to assess competitionbetweenHRP-conjugatedproteinA (Sigma)
(20g/ml) andFgBP1orFgBPM (serial dilutionsof0–50g/ml)
using plates coated with 5 g/ml reqIgG4 or reqIgG7. It was nec-
essary to use different concentrations of HRP-conjugated protein
GandproteinA in the assay because of the different binding affin-
ities of the two proteins for IgG.
Binding of RecombinantHuman Igs to FgBP—Twopreviously
described recombinant human IgG1/IgA1 domain-swap
mutants (18) were assessed for binding to FgBP1. In the first
mutant (123), the CH3 domain of human IgG1 is replaced
by the CH3 domain of human IgA1, whereas in the second
(123), the CH3 domain of human IgA1 is replaced by the
CH3 domain of human IgG1. Binding of FgBP1 to a recombi-
nant version of the human IgG3 allotype, IGHG3*01 or
IgG3m(5) (19), purified from transfectant supernatant by affin-
ity chromatography on 3-nitro-4-hydroxy-5-iodophenylac-
etate-Sepharose, was also investigated. This allotype is known
to lack the ability to bind protein A (20, 21). Binding analysis,
using recombinant human IgG1 and human IgA1, produced as
described previously (17), as positive and negative controls,
respectively, was carried out by ELISA as described above using
5 g/ml FgBP1 to coat and serial dilutions (up to 10 g/ml) of
recombinant Igs.
Site-directed Mutagenesis of eqIgG7 Heavy (H) Chain—Sin-
gle or double point mutations were introduced into the CH2 or
CH3 domains of the eqIgG7H-chain using aQuikChange II XL
site-directed mutagenesis kit (Stratagene, La Jolla, CA), follow-
ing the manufacturer’s instructions. Residues mutated in
eqIgG7 corresponded to those in human IgG1 responsible for
binding protein A or protein G (22, 23). Selected residues in
eqIgG7 were exchanged for the amino acid(s) present in the
non-FgBP-binding eqIgG subclasses, at positions where a non-
conservative amino acid alterationwas found. The fivemutants
generated are described in Table 1. Mutant antibodies were
purified and analyzed by SDS-PAGE and Western blotting as
previously described (16). The FgBP1 binding capacities of
mutant reqIgG7s were compared with that of wild-type
reqIgG7using biosensor analysis as described above except that
100-l injections of antibody were used.
Analysis of the Consequences of FgBP-IgG Binding on Com-
plement Activation—FgBP-mediated inhibition of C1q binding
and activation of the classic complement pathway by equine
IgG was assessed by ELISA using reqIgG3, reqIgG4, and
reqIgG7 (10 g/ml), as described previously (16), with the fol-
lowing modifications. After coating of wells with 3-nitro-4-hy-
droxy-5-iodophenylacetate-bovine serum albumin and subse-
quent incubation with recombinant Igs, plates were incubated
with serial dilutions of FgBP1 or FgBPM (0–10 g/ml in
3 M. Meehan and P. Owen, unpublished observations.
4 M. J. Lewis, B. Wagner, R. Irvine, and J. M. Woof, manuscript in preparation.
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PBS-T containing 0.5% bovine serum albumin) for 1 h at room
temperature. Plates were incubated then with either human C1q
protein (0.5 g/ml, Calbiochem) or human serum. In the former
case, binding of C1q to IgG was detected using sheep anti-hu-
man C1q-HRP, as previously described, whereas in the latter,
activation of the classic complement pathway was detected
using a 1/500 dilution of biotin-conjugated mouse anti-human
C4c (Quidel, Santa Clara, CA) followed by streptavidin-HRP
(1/500, Dako, Ely, Cambs, UK). C4c generation is a specific
marker for activation of the classic complement pathway (24).
Human C1q and human serum (as a source of complement)
were used rather than their equine equivalents because of the
availability of detection reagents for the human but not equine
proteins.Moreover, cross-species reactivity of IgG and comple-
ment components has been well demonstrated (25).
FIGURE 1. ELISA analysis of the interaction of recombinant equine Igs
with FgBP1. A, subclass specificity of the interaction. FgBP1 bound strongly
to IgG4 and IgG7, but the remaining five IgG subclasses and IgA showed little
or no binding. Open diamond, reqIgG1; cross, reqIgG2; open square, reqIgG3;
open circle, reqIgG4; open triangle, reqIgG5; plus sign, reqIgG6; closed triangle,
reqIgG7; closed square, reqIgA. B and C, pH dependence of the binding to
FgBP1. For both equine IgG4 (B) and IgG7 (C), binding to FgBP1 was most
efficient at pH 7.4–8.5. Closed diamond, pH 5.0; open square, pH 7.4; closed
triangle, pH 8.5. Binding of reqIgGs is expressed as absorbance obtained for
the binding to FgBP1 minus absorbance for binding to the FgBPM control
(binding to the latterwas typically0.15 absorbanceunits). Themean (S.E.)
of three independent experiments is shown.
FIGURE 2. Biosensor analysis of reqIgG binding to immobilized FgBP1.
Measurementswere carried out at different concentrations (0, 35, 50, 75, 100,
125, and 150 g/ml) for the soluble analyte equine IgG4 (A) and equine IgG7
(B), respectively. Measurements for the remaining five subclasses were car-
ried out at 150 g/ml only (C). The response curves shown represent specific
binding to FgBP1 (following subtraction of any nonspecific binding to the
FgBPM control). Only IgG4 and IgG7 showed concentration-dependent
interaction with immobilized FgBP1. RU, response units.
Interaction of FgBPwith Equine IgG4 and IgG7
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Analysis of FgBP-IgG Binding—Binding of recombinant
FgBP1 to the seven reqIgG subclasses and monomeric reqIgA
was first analyzed by ELISA. FgBP1 bound strongly to reqIgG4
and reqIgG7, with little or no binding to the remaining five
reqIgG subclasses or to reqIgA (Fig. 1A). Because IgG binding
by the bacterial IgG-binding proteins staphylococcal protein A
and streptococcal protein G is known to be pH-dependent (26),
we tested the effect of pH variation on the FgBP1-IgG interac-
tion (Fig. 1, B and C). An increase in pH from 7.4 to pH 8.5 had
little effect on binding, whereas a decrease in pH to 5.5 reduced
binding to roughly a third of that seen at physiological pH.
Hence, the pH dependence of IgG binding by FgBP is more
similar to that of protein A (strongest binding at pH 8) than to
that of protein G (strongest binding at pH 4–5) (26).
To establish the affinity of the FgBP-IgG interaction and con-
firm the equine IgG subclass specificity we used surface plas-
mon resonance measurements. These experiments gave iden-
tical results with regard to subclass specificity to those obtained
by ELISA, confirming that reqIgG4
and reqIgG7 are the predominant
subclasses capable of binding FgBP1
(Fig. 2). These subclasses share sim-
ilar affinity in the micromolar range
(Ka values of 6.96  106 M1 for
reqIgG7 and 6.79  106 M1 for
reqIgG4). Hence, binding affinity is
much lower than that of protein G
for IgG (26) and closer to that of
fragment B of protein A (27).
Localization of the FgBP Binding
Site on Equine IgG—Protein A and
protein G are known to bind in the
interdomain region of IgG Fc (22,
23) and have both been shown to
interact with reqIgG4 and reqIgG7,
although the binding to protein A is
relativelyweak (16). Therefore, we used a competition ELISA to
see if FgBP could inhibit binding of proteinsA andG to reqIgG4
and reqIgG7.We found that FgBP1, but not the non-IgG-bind-
ing control protein FgBPM, was able to compete with both
protein A and protein G for binding to reqIgG4 and reqIgG7
(Fig. 3). This inhibition was concentration-dependent, and
binding of both protein A and protein G was negligible at the
maximum concentration of FgBP1 (50 g/ml). These findings
suggest that the FgBP binding site(s) on reqIgG4 and reqIgG7
overlap with those of protein A and protein G in the Fc inter-
domain region.
To determine whether one or both of the IgG Fc domains
contribute to FgBP binding, we utilized recombinant human
IgG1 and two human IgG1/IgA1 domain-swap mutants. Using
biosensor analysis (data not shown), we found that human IgG1
interacted with FgBP1 with an affinity (Ka of 5.71  106 M1)
only slightly lower than that of reqIgG4 and reqIgG7. Like
eqIgA, human IgA1 was found not to bind FgBP1 (Fig. 4). A
domain-swap mutant lacking the CH2 domain but retaining
the CH3 domain of IgG1 (123) was able to bind to FgBP1,
but at a much reduced level compared with that of wild-type
human IgG1 (Fig. 4). However, FgBP1 binding was completely
absent for a mutant retaining the CH2 domain but lacking the
CH3domain of IgG1 (123) (Fig. 4). Hence, both Fc domains
are required formaximal binding, but the CH3 domain appears
to be the most critical.
In addition, we included in this analysis a recombinant
human IgG3 antibody of the IGHG3*01 allotype. IgG3 allotypes
capable of binding protein A possess a His residue at position
435 within the interaction site for protein A. However, the
IGHG3*01 allotype carries an Arg at this critical CH3
domain residue and is unable to bind protein A (20, 21). We
found that the IGHG3*01 allotype did not bind FgBP1, indi-
cating that residue 435 is critical also for interaction with
FgBP (Fig. 4).
To further localize the FgBP binding site on equine IgG, we
generated five IgG7 mutants with single or double point muta-
tions in the regions corresponding to the protein A/protein G
binding sites (Table 1). Analysis of the IgG7 mutants by SDS-
PAGE and Western blotting revealed that all the mutant
FIGURE 3. ELISA analysis of competition for binding to reqIgG4 and reqIgG7between FgBPproteins and
protein A andproteinG. A, competition of binding of HRP-conjugated protein G (0.25g/ml) to reqIgG4 and
reqIgG7 coated at 2.5g/ml.B, competitionof bindingofHRP-conjugatedproteinA (20g/ml) to reqIgG4and
reqIgG7 coated at 5 g/ml. The figures shows mean (S.E.) of three independent experiments. reqIgG4 with
FgBP1 competitor (closed circle) and FgBPM competitor (open circle); reqIgG7 with FgBP1 competitor (open
triangle) and FGBPM competitor (closed triangle).
FIGURE 4. ELISA analysis of FgBP1 binding to human IgG1, human IgG1/
IgA1domain-swapmutantsandhuman IgG3allotype IGHG3*01.Binding
of Igs is expressed as absorbance obtained for the binding to FgBP1 minus
absorbance for binding to the FgBPM control (binding to the latter was
typically 0.15 absorbance units). Fig. shows mean (S.E.) of three inde-
pendent experiments. Open diamond, human IgG1; open triangle, human
IgA1; closed square, 123 mutant; open circle, 123 mutant; cross,
human IgG3 IGHG3*01 allotype.
Interaction of FgBPwith Equine IgG4 and IgG7
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reqIgG7s assembled like wild-type reqIgG7 and retained the
anticipated reactivity with antigen and both polyclonal and
monoclonal anti-equine IgGb (i.e. anti-eqIgG4 and -eqIgG7)
reagents (Fig. 5). These test outcomes and the fact that the
substitutions were based on residues present in other equine
IgG isotypes suggest that the likelihood of unintended confor-
mational disruption in the mutants is extremely low, allowing
us to draw meaningful conclusions on the relative contribu-
tions of the mutated residues to FgBP binding. Binding of the
mutant reqIgG7s to FgBP1was analyzed using surface plasmon
resonance experiments (Fig. 6). Mutants M252K and K382Q
both showed decreased FgBP1 binding compared with wild-
type reqIgG7. However, the 45-fold decrease in FgBP1 bind-
ing by M252K (Ka of 1.53  105 M1) was more dramatic
than the 2.4-fold decrease shown by K382Q (Ka of 2.91 106
M1). Mutant H433R showed a small (1.7-fold, Ka of 4 106
M1) reduction in FgBP1 binding capacity compared with
wild-type reqIgG7. However, the double point mutants
HN433/434EH and HY435/436TV showed drastically
impaired abilities to bind FgBP1, retaining5% of the bind-
ing capacity of wild-type reqIgG7. The FgBP1 binding af-
finities and interdomain site sequence alignment of the
tested IgGs are summarized in Fig. 7. Taken together these
results suggest that the binding site on IgG for FgBP encom-
passes some of the same interdomain residues as those
involved in interaction with protein A and protein G. Resi-
dues in the Leu251–Ser254 and the Leu432–Tyr436 loops are
particularly implicated. Comparison of the binding affinities
of mutants H433R and HN433/434EH suggests that either
His433 is not critical for FgBP binding, or that alteration of
FIGURE 5. Analysis of reqIgG7 mutants by SDS-PAGE and Western blot-
ting. Proteins were run under non-reducing (A) and reducing (B and C) con-
ditions and stainedwith Coomassie Brilliant blue (A and B) or immunoblotted
and probed with polyclonal goat anti-horse IgGb which recognizes reqIgG4
and reqIgG7 (C). Lane 1, wild-type reqIgG7; lane 2, M252K; lane 3, K382Q; lane
4, H433R; lane 5, HN433/434EH; lane 6, HY435/436TV.
FIGURE6.Biosensoranalysisof thebindingofFgBP1 to reqIgG7mutants.
Injections of 100l (30l/min) of reqIgG7s at 0, 5, 10, 25, 35, 50, 75, 100, 125,
and150g/ml are shown.A,wild-type reqIgG7;B,M252K;C, K382Q;D, H433R;
E, HN433/434EH; F, HY435/436TV. The response curves shown represent spe-
cific binding to FgBP1 (following subtraction of any nonspecific binding to
the FgBPM control).
TABLE 1
Names and description of reqIgG7mutants
Mutant Descriptiona eqIgG subclasses carrying the sameresidues as those substituted
M252K Met252 in CH2 domain substituted with Lys IgG5
K382Q Lys382 in CH3 domain substituted with Gln IgG1, IgG2, IgG3, IgG5, IgG6
HN433/434EH His433 in CH3 domain substituted with Glu, Asn434 in CH3 domain substituted with His Glu433 in IgG5
His434 in IgG6
H433R His433 in CH3 domain substituted with Arg IgG6
HY435/436TV His435 in CH3 domain substituted with Thr, Tyr436 in CH3 domain substituted with Val Thr435 in IgG6
Val436 in IgG3
a Numbering corresponds to human IgG1 numbering.
Interaction of FgBPwith Equine IgG4 and IgG7
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this residue to a positively charged amino acid such as argi-
nine (as in H433R) can be tolerated without significant
impact on the affinity of the interaction. In contrast, residues
His435 and/or Tyr436 appear to be critical for the interaction,
because in both instances where these residues are substi-
tuted (with Arg435 and Phe436 in human IgG3 allotype
IGHG3*01 and with Thr435 and Val436 in reqIgG7 mutant
HY435/436TV) binding to FgBP1 is ablated. Overall, we can
conclude that the binding site for FgBP on reqIgG Fc appears
to center on the interdomain region, utilizing residues com-
mon to both the protein A and protein G binding sites.
Impact of FgBP Binding to IgG on Complement Activation—
We have previously demonstrated that reqIgG1, reqIgG3,
reqIgG4, and reqIgG7 bind strongly to C1q and activate the
classical complement pathway (16). To gain an insight into
the physiological consequences of FgBP binding to eqIgG4
and eqIgG7, we investigated whether FgBP1 could inhibit
their ability to bind C1q and activate the classical comple-
ment pathway. We found that FgBP1 was able to disrupt C1q
binding and complement activa-
tion by reqIgG4 and reqIgG7 (Fig.
8). In contrast, FgBP1 was unable
to disrupt C1q binding and com-
plement activation by reqIgG3,
which we have shown binds poorly
or not at all to FgBP1 (Fig. 8). The
control protein, FgBPM, had no
effect on C1q binding or comple-
ment activation. With the highest
concentration of FgBP1 used (10
g/ml), C1q binding and comple-
ment activation by reqIgG4 and
reqIgG7 decreased to 50 and 40%,
respectively, of that seen in the
absence of FgBP1. This partial
rather than complete inhibition of
antibody-mediated complement
activation may be a consequence
of using soluble rather than cell-
bound FgBP (see “Discussion”
below).
DISCUSSION
Ig-binding proteins have been
identified in a range of bacteria, and
their diversity in Ig binding charac-
teristics in terms of Ig isotype, sub-
class, and species has long been rec-
ognized. The horse has an unusually
large number of IgG subclasses,
which vary in their structural and
functional attributes (14–16). In
this study we addressed the eqIgG
subclass specificity of FgBP and
found that this bacterial protein is
highly specific for only two (eqIgG4
and eqIgG7) of the seven eqIgG sub-
classes. eqIgG4 and eqIgG7 are 97%
identical at the amino acid level, and prior to genomic identifi-
cation were together thought to comprise a single subclass
termed IgGb (15, 28). For all the binding characteristics and
effector functions thus far tested, these two subclasses share
common features, presumably due to their high sequence sim-
ilarity (16).
We have demonstrated that FgBP binds to the interdomain
region of IgG Fc and that both of the Fc domains are required
for full binding. The residues implicated in our mutagenesis
studies as critical for binding to FgBP are known to mediate
interaction with staphylococcal protein A and streptococcal
protein G also (22, 23). Indeed, there is a striking overlap of the
regions recognized by these three distinct bacterial proteins
(Fig. 9), despite the fact that they derive from very different
streptococcal and staphylococcal strains and these bacteria are
pathogenic in different mammalian species.
Even more remarkably, the fact that these unrelated IgG-
binding proteins bind to similar sites in the IgG interdomain
region parallels the situation for the unrelated bacterial IgA
FIGURE 7.Amino acid alignments of reqIgG subclasses and reqIgG7mutants showing only CH2 andCH3
residues critical for interaction with protein A and protein G. Residue numbers (shown above sequences)
correspond to human IgG1 numbering. In the corresponding hIgG1 sequence (shown for comparison at the
top), residues implicated in interactions are indicated as follows: protein G, normal text; protein A, underlined;
bothproteinA andproteinG,box. The corresponding sequence for human IgG3 allotype IGHG3*01 (hIgG3*01)
is also shown. In the middle section, the FgBP-binding subclasses eqIgG4 and eqIgG7 are shown above the
non-binding subclasses. reqIgG7mutants are shown in the lower partof the figure,with substitutions encircled.
Ka values for interaction with FgBP1 are shown on the right. TLTD, too low to detect.
FIGURE 8.Disruption of antibody-mediated complement activation by FgBP1. Increasing concentrations
of FgBP1 were able to disrupt C1q binding, detected using anti-C1q antibody (A), and activation of the classical
complement pathway, detected using anti-C4c antibody (B), by reqIgG4 and reqIgG7 but not by reqIgG3, which
binds poorly to FgBP1. Closed diamond, reqIgG3; open square, reqIgG4; closed triangle, reqIgG7. In each case, C1q
binding/activation are shown as a percentage of the binding/activation seen in the absence of FgBP1. The figure
showsmean (S.E.) of three independent experiments.
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binding proteins Sir22 from S. pyogenes, protein fromgroupB
streptococcus, and SSL7 from Staphylococcus aureus, which all
bind to the Fc domain interface in human IgA (29–31) (Fig. 9).
Although a different immunoglobulin class is involved, again
we see the equivalent region being targeted by proteins pro-
duced by very different bacterial pathogens. Thus, it seems that
convergent evolution may have favored the appearance of bac-
terial proteins that bind to the CH2/CH3 interface in IgG and
IgA. This interdomain region, in IgG at least, has been recog-
nized as one of only a limited number of regions on the Ig
surface that is particularly suited to protein-protein interaction
(32, 33).
The evolutionary reasons why such sites of relative vulnera-
bility have been retained on the surface of Ig Fc regions are
likely to be complex (34) but most probably relate to their roles
as interaction sites for key host receptors. In IgG, for example,
the Fc interdomain region forms the interaction site for
FcRn, the so-called neonatal Fc receptor that mediates a
number of processes fundamental to IgG function, including
regulation of IgG turnover and transepithelial transfer of IgG
(35). For IgA, the CH2/CH3 interdomain region serves as the
interaction site for its specific Fc receptor, FcRI, which
triggers efficient elimination mechanisms against IgA-
coated pathogens (18, 36).
Despite the marked overlap in their binding sites on IgG, the
eqIgG subclass specificities for FgBP, protein G, and protein A
are distinct. Although FgBP binds almost exclusively to eqIgG4
and eqIgG7, protein G binds strongly to eqIgG1, eqIgG4, and
eqIgG7 and shows intermediate binding to eqIgG3, low binding
to eqIgG2 and eqIgG6, and no binding to eqIgG5 (16). Binding
of eqIgGs to proteinA is generally quite lowwith the subclasses
binding in the following order eqIgG1 eqIgG3 eqIgG4
eqIgG7  eqIgG2  eqIgG5  eqIgG6 (16). His435 in the
CH3 domain of IgG, which is critical for binding to protein
A, either alone or together with its neighbor Tyr436, also
appears to be a requirement for binding to FgBP. Thus devi-
ations from the His435-Tyr436 motif may account, at least in
part, for the inability of eqIgG6 and eqIgG2 to bind FgBP.
Although our mutagenesis experiments have pinpointed
amino acid differences that may account for the deficiency of
some of the eqIgG subclasses in FgBP binding, we predict
that there may be additional residues in the eqIgG Fc outside
the protein A and protein G binding sites that make unique
contributions to the IgG-FgBP interaction.
Together eqIgG4 and eqIgG7 are themost prevalent forms of
IgG in serum and are also found in mucosal secretions (37).
Furthermore, both subclasses are able to stimulate a strong res-
piratory burst from equine peripheral blood leukocytes and
FIGURE 9. Interaction sites for streptococcal and staphylococcal Ig-binding proteins on IgG and IgA Fc regions. The CH2 and CH3 domains of the heavy
chains of IgG (A–C) (PDB accession: 1FC1) and IgA (D–F) (PDB accession: 1OW0) are shown in light blue and dark blue, respectively. Residues shown to be critical
for interaction bymutagenesis studies and/or by x-ray crystallography of complexes are highlightedby spheres.A, FgBP from S. equi in purple; B, proteinG from
groupCandgroupGstreptococci in red;C, proteinA from S. aureus in yellow;D, Sir22 from S. pyogenes inorange; E,protein fromGroupBstreptococcus inpink;
F, SSL7 from S. aureus in green. Remarkably, all the Ig-binding proteins target the CH2-CH3 domain interface, regardless of specificity for IgG or IgA, strepto-
coccal or staphylococcal origin, or host species (equine or human).
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effectively activate complement via the classical pathway (16).
Accumulated evidence has highlighted that antibodies, in par-
ticular those that recognize FgBP, play a vital role in protection
against strangles (38–40). Furthermore, FgBP-specific IgGb
(i.e. eqIgG4/eqIgG7) has been recognized as the predominant
IgG subclass present in the sera of acute and convalescent
strangles cases and in the nasal mucosa during the acute
response (13). The non-immune binding of antibodies by bac-
terial immunoglobulin binding proteins is presumed to subvert
the host immune response. Functionally, this could be through
prevention of initial antibody binding to bacterial epitopes, eva-
sion of detection by other components of the immune response
by coating of bacteria with host antibody, or by blocking of
Fc-mediated effector functions such as complement activation
or Fc-receptor binding. Several studies have investigated the
ability of bacterial Ig binding proteins to interfere with the
effector functions of IgG. The majority of available evidence
appears to argue against the ability of such proteins to inhibit
the binding of IgG to FcR on phagocytic cells (41). However,
protein A has been shown to be capable of inhibiting C1q bind-
ing to surface-immobilized IgG, thereby preventing comple-
ment activation (42). Similarly, the binding of proteinH from S.
pyogenes to surface-immobilized IgG can inhibit C1q binding
and partially block complement-mediated lysis (42). In the cur-
rent study, binding of FgBP to surface-immobilized eqIgG4 and
eqIgG7 was clearly able to disrupt the binding of C1q and pre-
vent subsequent activation of the classical complement path-
way. Our results indicate that the observed inhibition of C1q
binding and complement activation depends on the binding of
FgBP to eqIgG, because when an eqIgG subclass that is unable
to bind FgBP is used (eqIgG3), no inhibition is seen. Because
specific antibody and complement have both been shown nec-
essary to combat S. equi (43), such targeting of the major com-
plement-activating eqIgG subclasses may afford the bacterium
an effective means to disrupt antibody-mediated elimination.
The observed FgBP-mediated inhibition of bothC1q binding
to IgG and complement activation, although substantial, was
not complete. Our use of a soluble version of FgBP may have
underestimated the potency, in this regard, of FgBP,which in its
natural form is an abundant cell wall-associated protein (5–7).
Onemight speculate that anchoring of IgG close to the bacterial
surface by cell wall-bound FgBP is likely to increase the chance
of steric hindrance. Thus the approach and binding of such a
large molecule as C1q would be compromised, resulting in
more complete inhibition of the complement pathway. Support
for this notion comes from related studies with protein G.
Although one study found soluble streptococcal protein G
unable to block both C1q binding to IgG and complement-
mediated lysis of IgG-sensitized red blood cells (42), another
demonstrated that, when IgG is bound by bacterial cell-surface
proteinG, interactionwith C1q is completely blocked (44). The
authors of the second study proposed that the presence of pro-
tein G in a defined orientation and spacing on the streptococcal
cell surface facilitates inhibition of the interaction of C1q with
proteinG-bound IgG. In a similar fashion, onemight argue that
the particular spatial arrangement of FgBP on the surface of S.
equi cells may effectively prevent the approach and interaction
of bulky C1q molecules with any IgG that is bound to FgBP.
Thuswe consider that there are good reasons to believe that the
FgBP-IgG interaction is likely to make an important contribu-
tion to the pathophysiology of strangles, at least in part through
inhibition of complement-mediated clearance mechanisms.
Under thephysiological conditions of plasma, onemight expect
binding of both fibrinogen and IgG to FgBP, assuming access/
steric hindrance is not an issue. Further experiments will be nec-
essary to assess the impact that fibrinogen binding might have on
the interaction of IgGwith FgBP and on the prevalentmechanism
of inhibition of complement activation (45).
S. equi has evolved multiple secreted and cell surface-associ-
ated factors that interact with host proteins and promote
adherence and/or help to evade immune responses (1). These
include another immunoglobulin-binding protein, the2-mac-
roglobulin, albumin, and IgG-binding protein or EAG (46). The
equine IgG subclass specificity and the biological effects of IgG
binding by EAG have not been elucidated and would make an
informative comparison with FgBP, particularly because this
protein is the subject of vaccine studies (47–49). Interestingly,
protein ZAG, the homologue of EAG present in S. equi subsp.
zooepidemicus, is reported to bind IgG from a broader range of
species than FgBP and to bind horse IgG (subclass not speci-
fied) with a much higher affinity (Ka of 1 1010 M1) (50).
In conclusion, we have shown that the Fc-mediated binding
of equine IgG by S. equi FgBP is highly specific for the eqIgG4
and eqIgG7 subclasses. The FgBP-IgG interaction provides an
effective means by which S. equi subsp. equi can circumvent
antibody effector function. In common with several other
streptococcal and staphylococcal IgG- and IgA-specific
Ig-binding proteins, FgBP binds to the domain interface of the
Ig Fc region, illustrating a commonmode of interaction that has
been adopted by these important virulence factors.
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